Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma

Medical Oncology

Volumn 23, Issue 4, 2006, Pages 543-548

  Karagol, Hakan ^a   Saip, Pinar ^b   Uygun, Kazim ^a   Kucucuk, Seden ^b   Aydiner, Adnan ^b   Topuz, Erkan ^b  

^a TRAKYA UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Endometrial carcinoma; Metastasis or recurrence; Prognostic factors; Systemic treatment

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; PACLITAXEL;

ADULT; ARTICLE; CALCULATION; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER SURVIVAL; CHI SQUARE TEST; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HISTOLOGY; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; MEDICAL RECORD; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECURRENT CANCER; RETROSPECTIVE STUDY; STUDENT T TEST; SURVIVAL TIME; SYSTEMIC DISEASE; SYSTEMIC THERAPY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MEGESTROL ACETATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; PACLITAXEL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33846996848     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:23:4:543     Document Type: Article

References (13)

1. Creasman WT. Endometrial cancer. Limited disease: role of surgery. Semin Oncol 1994;21:79-83.
2. Pawinski A, et al. Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomised phase II study of the EORTC Gynecological Cancer Cooperative Group. Eur J Obstet Gynecol Reprod Biol 1999;86:179-183.
3. Elit L, Hirte H. Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer. Curr Opin Obstet Gynecol 2002;14:67-73.
4. Lentz SS. Advanced and recurrent endometrial carcinoma: hormonal therapy. Semin Oncol 1994;21:100-106.
5. Barakat RR, Park RC, Grigsby PW. Corpus: epithelial tumors. In: Hoskins WJ, Perez CA, Young RC (eds). Principles and Practice of Gynecologic Oncology. Lippincott Williams and Wilkins: Philadelphia, 1997, pp. 859-896.
6. Grigsby PW, et al. Clinical stage I endometrial cancer: prognostic factors for local control and distant metastasis and implications of the new FIGO surgical staging system. Int J Radiat Oncol Biol Phys 1992;22:905-911.
7. Mariani A, Webb MJ, Keeney GL, Aletti G, Podratz KC. Assessment of prognostic factors in stage IIIA endometrial cancer. Gynecol Oncol 2002;86:38-44.
8. Steiner E, et al. Multivariate independent prognostic factors in endometrial carcinoma: a clinicopathologic study in 181 patients: 10 years experience at the department of obstetrics and gynecology of the Mainz University. Int J Gynecol Cancer 2003;13:197-203.
9. Prat J. Prognostic parameters of endometrial carcinoma. Hum Pathol 2004;35(6):649-662.
10. Thigpen JT, Buchsbaum HJ, Mangan C, Blessing JA. Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma. A Gynecologic Oncology group study. Cancer Treat Rep 1979;63:21-27.
11. Thigpen JT, Blessing JA, Homesley H. A phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Ocology Group study. Gynecol Oncol 1989;33:68-70.
12. Long HJ, Pfeifle DM, Wieand HS. Phase II evaluation of carboplatin in advanced endometrial carcinoma. J Natl Cancer Inst 1988;80:276- 278.
13. Lincoln S, Blessing JA, Lee RB, Rocereto TF. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003;88:277-281.